Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Chinese Journal of Nosocomiology ; 30(17):2579-2582, 2020.
Article | WHO COVID | ID: covidwho-923127

ABSTRACT

OBJECTIVE: To explore the clinical characteristics of patients with Corona Virus Disease 2019(COVID-19) and the treatment options METHODS: The clinical data of 50 patients with COVID-19 who were treated in the Sino-French New City Campus of Tongji Hospital, Huazhong University of Science and Technology from Feb 2, 2020 to Feb 28, 2020 were retrospectively analyzed The clinical characteristics and treatment options of the patients were analyzed, the clinical laboratory test indexes were observed before and after the treatment, and the cure rate was analyzed RESULTS: The major clinical symptoms of the 50 patients with COVID-19 included cough, expectoration, dyspnea, fever, diarrhea and muscle soreness The imaging findings of all the patients were characterized by chest radiograph/chest CT interstitial lesions in both lungs All of the patients were given drug therapy and oxygen therapy The drug treatment options included hormone plus antibacterial therapy, antiviral plus hormonal therapy, antiviral plus antibacterial therapy, antiviral plus hormone plus antibacterial therapy;the proportion of the patients who were given antiviral plus hormone plus antibacterial therapy was the highest(72%) Arbidol was the most commonly used antiviral drug, with the utilization rate 98%;methylprednisolone was the most commonly used hormone, with the utilization rate 80%;moxifloxacin was the most commonly used antibiotic, with the utilization rate 72% Among the 50 patients, 3 patients had increased white blood cell(WBC) counts, and 4 patients had decreased WBC counts;60% of the patients had increased percentage of neutrophils, and 74% of the patients had decreased lymphocytes counts The WBC counts and lymphocytes level were significantly higher after the treatment for 7 and 14 days than before the treatment(P<0 05);the percentage of neutrophils and PCT level were significantly lower after the treatment than before the treatment(P<0 05) CONCLUSION: The detection rate of interstitial lung lesions is high among the patients with COVID-19, and most of the patients are complicated with cough, expectoration, dyspnea, fever, diarrhea and muscle soreness Arbidol, combined with hormones or antibiotics on the basis of actual situation, may effectively improve the serological indexes of the patients with COVID-19 and raise the cure rate

2.
Ann Transl Med ; 8(12): 747, 2020 Jun.
Article in English | MEDLINE | ID: covidwho-640177

ABSTRACT

Background: The coronavirus disease 2019 (COVID-19) virus has a high incidence rate and strong infectivity. The diagnosis and evaluation of familial outbreaks requires a collective consideration of epidemiological history, molecular detection methods, chest computed tomography (CT), and clinical symptoms. Methods: A group of family patients with COVID-19 diagnosed in Guizhou, China, in February 2020, was retrospectively analyzed. As of March 1, all patients in the group have been discharged from hospital. This study tracked all patients in the group. We report the epidemiology, radiological characteristics, treatment, and clinical outcomes of these patients. Results: We collected a group of 8 clustered cases (3 men and 5 women) from a family with confirmed COVID-19 infection. In the first admission diagnosis, according to the degree of clinical symptoms, the 8 patients were defined as mild type (4/8) or moderate type (4/8). They were also divided according to the CT findings into early period (1/8), progressive period (3/8), and negative on CT scan (4/8); for the first 4 patients, the corresponding CT image scores were 1, 4, 5, and 5 respectively. In this group of COVID-19 patients, half of the patients showed occult clinical manifestations and negative CT performance. We defined these patients as COVID-19-infected patients, or asymptomatic carriers. Conclusions: The family cluster analysis indicated that COVID-19-infected patients (asymptomatic carriers) and symptomatic COVID-19 patients are distinct but coexistent. This may indicate that the infectivity and virulence of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has decreased. In order to block the transmission pathway of this virus before it spreads, we need to identify the presence of asymptomatic carriers as early as possible.

3.
Biochim Biophys Acta Gen Subj ; 1864(10): 129672, 2020 10.
Article in English | MEDLINE | ID: covidwho-601229

ABSTRACT

BACKGROUND: Exposure to PM2.5 has been associated with increased morbidity and mortality of lung diseases although the underlying mechanisms have not been fully uncovered. Airway inflammation is a critical event in the pathogenesis of lung diseases. This study aimed to examine the role of oxidative stress and epidermal growth factor receptor (EGFR) in PM2.5-induced pro-inflammatory response in a human bronchial epithelial cell line, BEAS-2B. METHODS: BEAS-2B cells were exposed to 0, 20, 50, 100 and 150 µg/ml of PM2.5. Secretion of pro-inflammatory mediators including interleukin-6 (IL-6), IL-8 and IL-1ß was determined using enzyme linked immunosorbent assay. Levels of intracellular reactive oxygen species (ROS) were determined using flow cytometry. Phosphorylation of the EGFR was examined with immunoblotting. RESULTS: PM2.5 exposure increased the secretion of IL-6, IL-8, and IL-1ß in a concentration-dependent fashion. Moreover, exposure to PM2.5 elevated intracellular levels of ROS, and phosphorylation of the EGFR (Y1068). Pretreatment of BEAS-2B cells with either an antioxidant or a specific EGFR inhibitor significantly reduced PM2.5-induced IL-6, IL-8 and IL-1ß secretion, implying that both oxidative stress and EGFR activation were involved in PM2.5-induced pro-inflammatory response. Furthermore, pre-treatment of BEAS-2B cells with an antioxidant significantly blunted PM2.5-induced EGFR activation, suggesting that oxidative stress was required for PM2.5-induced EGFR activation. CONCLUSION: PM2.5 exposure induces pro-inflammatory response in human bronchial epithelial cells through oxidative stress-mediated EGFR activation.

5.
Viruses ; 12(4)2020 03 27.
Article in English | MEDLINE | ID: covidwho-17449

ABSTRACT

The outbreak of emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) in China has been brought to global attention and declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Scientific advancements since the pandemic of severe acute respiratory syndrome (SARS) in 2002~2003 and Middle East respiratory syndrome (MERS) in 2012 have accelerated our understanding of the epidemiology and pathogenesis of SARS-CoV-2 and the development of therapeutics to treat viral infection. As no specific therapeutics and vaccines are available for disease control, the epidemic of COVID-19 is posing a great threat for global public health. To provide a comprehensive summary to public health authorities and potential readers worldwide, we detail the present understanding of COVID-19 and introduce the current state of development of measures in this review.


Subject(s)
Antiviral Agents/therapeutic use , Clinical Laboratory Techniques/methods , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Betacoronavirus , China , Coronavirus Infections/diagnosis , Genome, Viral , Humans , Public Health , Viral Vaccines
SELECTION OF CITATIONS
SEARCH DETAIL